Abstract Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …

Abstract Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million
people worldwide, but effective care and therapy have yet to be discovered. We conducted …

The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin‐6 (IL‐6) receptor,
in patients with coronavirus disease‐2019 (COVID‐19) patients has led to conflicting results …

Introduction: Acute lung injury is associated with dysfunctional immune response to SARS-
CoV-2. This leads to CRS, which require immunomodulatory treatments aiming to limit the …

Background/aim: Since the outbreak of the COVID-19, numerous therapies to counteract this
severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 …

Background COVID-19 is an ongoing threat to society. Patients who develop the most
severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has …

Importance Pneumonia due to COVID-19 can lead to respiratory failure and death due to the
development of the acute respiratory distress syndrome. Tocilizumab, a monoclonal …

COVID‐19 leads to mortality of several patients and the cytokine storm is reportedly critical
in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 …

Tocilizumab is an interleukin receptor inhibitor that has been used in patients with COVID-19
pneumonia. There are recent randomized controlled trials (RCTs) that evaluated the efficacy …

ABSTRACT BACKGROUND: Tocilizumab is an anti-human interleukin 6 receptor
monoclonal antibody that has been used to treat coronavirus disease 2019 (COVID-19) …